Real-World Safety and Health Care Resource Utilization of Teclistamab Under an Outpatient Model for Step-Up Dosing Administration
JCO Oncology Practice · 2025-05 · 21 (5) · 702-709
DOI: 10.1200/op-24-00489 ↗Kurz gefasst
Fachartikel in der Zeitschrift JCO Oncology Practice, 2025-05. Verfasst von Tyler B Sandahl und 20 weiteren Autor:innen. Beteiligte Einrichtung: Mayo Clinic, Rochester, MN. Hauptthemen laut MEDLINE: Multiple Myeloma, Health Resources, Patient Acceptance of Health Care. Die Arbeit wurde bisher 21-mal zitiert (Crossref) und nennt 15 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS.
Abstract (Originalsprache)
PURPOSE Teclistamab is initiated with a step-up dosing (SUD) schedule to mitigate the risk of cytokine release syndrome (CRS) and immune effector cell–associated neurotoxicity syndrome (ICANS). Early teclistamab users commonly received SUD in a hospital setting. This study aimed to evaluate safety and health care resource utilization (HRU) in real-world patients with multiple myeloma who initiated teclistamab SUD in an outpatient setting. METHODS This was a retrospective study using Mayo Clinic's electronic medical records from October 26, 2022, to October 31, 2023. Patient characteristics were summarized for all patients treated with teclistamab and separately for patients who started SUD outpatient. SUD pattern, safety, HRU, and post-SUD dosing schedule were described in patients with complete SUD. RESULTS At data cutoff, 65 patients received ≥1 teclistamab dose, including 58 patients who initiated SUD outpatient (median age, 69.2 years; male, 63.8%; White, 89.7%). Among 57 patients who completed SUD in an outpatient setting, all received premedications on the days of teclistamab administrations per label recommendation; 18 (31.6%) developed CRS (13 grade 1, four grade 2, and one grade 4) and two developed ICANS (one each with grade 2 and 4). All CRS and ICANS resolved with supportive care and all patients continued treatment. Eighteen patients were admitted to the hospital for CRS treatment, with a median CRS-related hospital stay of 2 days per admission. Most (60%) doses during SUD required
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Mayo Clinic, Rochester, MN.
- Mayo Clinic, Phoenix, AZ.
- Mayo Clinic, Jacksonville, FL.
- Janssen Scientific Affairs, LLC, Horsham, PA.
- nference Inc, Cambridge, MA.
- Janssen R&D, LLC, Raritan, NJ.
ORCID-Profile: Tyler B Sandahl, Scott A Soefje, Sikander Ailawadhi, Ricardo Parrondo, Dee Lin, Bingcao Wu, Ediz S Calay, Tyler E Wagner, Laura Hester, Karthik Murugadoss, Dina Gifkins, Yi Lin, Shaji Kumar
Förderung
- NCI NIH HHS
Zitieren
APA
Sandahl, T. B., Soefje, S. A., Fonseca, R., Ailawadhi, S., Parrondo, R., Lin, D., Wu, B., Calay, E. S., Silvert, E., Kim, N., Carpenter, C., Wagner, T. E., Fowler, J., Hester, L., Rangarajan, N., Murugadoss, K., Marshall, A., Stoy, P., Gifkins, D., …, & Kumar, S. (2025). Real-World Safety and Health Care Resource Utilization of Teclistamab Under an Outpatient Model for Step-Up Dosing Administration. JCO Oncology Practice, 21(5), 702-709. https://doi.org/10.1200/op-24-00489
Vancouver
Sandahl TB, Soefje SA, Fonseca R, Ailawadhi S, Parrondo R, Lin D, et al. Real-World Safety and Health Care Resource Utilization of Teclistamab Under an Outpatient Model for Step-Up Dosing Administration. JCO Oncology Practice. 2025;21(5):702-709. doi:10.1200/op-24-00489
BibTeX
@article{Sandahl2025,
author = {Sandahl, Tyler B and Soefje, Scott A and Fonseca, Rafael and Ailawadhi, Sikander and Parrondo, Ricardo and Lin, Dee and Wu, Bingcao and Calay, Ediz S and Silvert, Eli and Kim, Nina and Carpenter, Corinne and Wagner, Tyler E and Fowler, Jessica and Hester, Laura and Rangarajan, Nivedita and Murugadoss, Karthik and Marshall, Alexander and Stoy, Patrick and Gifkins, Dina and Lin, Yi and Kumar, Shaji},
title = {Real-World Safety and Health Care Resource Utilization of Teclistamab Under an Outpatient Model for Step-Up Dosing Administration},
journal = {JCO Oncology Practice},
year = {2025},
volume = {21},
number = {5},
pages = {702--709},
doi = {10.1200/op-24-00489}
}
EUVIMED